Pharma.ai Updates
Summer 2025
July 10, 10 a.m. EST
Unlock the Power of Novel Biologics Engineering with AI
Generative Biologics is an advanced, AI-powered platform for designing and optimizing different types of biologics including peptides, nanobodies, and antibodies tailored for specific targets.
Generative Biologics Capabilities
-
Built-in
predictive modelsUse pre-trained models to predict and optimize developability properties.
Generate novel biologics
Biology42: Generative Biologics is designed for creation at speed and scale.
With over 10 generative and predictive models, supported by physics-based tools, our platform produces novel, diverse, and high-quality biologics, and can effectively target hard-to-drug proteins and specific epitopes. Our method enables the generation of binder candidates in less than 24 hours, accelerating discovery where it matters most.
With over 10 generative and predictive models, supported by physics-based tools, our platform produces novel, diverse, and high-quality biologics, and can effectively target hard-to-drug proteins and specific epitopes. Our method enables the generation of binder candidates in less than 24 hours, accelerating discovery where it matters most.
Predict biomolecule properties
Identify the best candidates for further development by assessing their affinity and developability early in the discovery process.
Optimize your biologics
Simultaneously optimize multiple properties of your biomolecules. Use our optimization workflow to balance both affinity and developability, leveraging a combination of built-in and user-trained models for tailored results.
Train your own model
Build project-specific models using your own data to achieve high-accuracy predictions and let AI guide your experiments, reducing both time and cost. Our proprietary models are designed to work with specific biologic types, achieving higher precision compared to traditional LLMs.
Flexible Business Models
Choose stand alone technology access or combine our software with Pharma.ai services for a data-driven AI-partnership.
Please Note: If you are seeking information about participating in a clinical trial or treatment options, please consult your healthcare provider or primary care physician.
